Cover Image
Market Research Report

Onychomycosis - Market Insights, Epidemiology and Market Forecast 2028

Published by DelveInsight Business Research LLP Product code 773931
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Onychomycosis - Market Insights, Epidemiology and Market Forecast 2028
Published: January 1, 2019 Content info: 100 Pages
Description

DelveInsight's "Onychomycosis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Onychomycosis epidemiology and market outlook for the

Onychomycosis (Tinea Unguium or nail fungus) can be described as a fungal infection that causes fingernails or toenails to thicken, discolor, disfigure, and split. It is a common condition that begins as a white or yellow spot under the tip of the fingernail or toenail. As the fungal infection goes deeper, nail fungus may cause the patient's nails to crumble at the edge. In case the condition is mild and not painful, it may not be required to consult a doctor. However, if the nail fungus is painful and has caused severe thickening of the nails, self-care steps and medications may help. If the problem is caused by a bacterium, the condition is called paronychia.

Onychomycosis occurs from the overgrowth of fungi in, under, or on the nail. Fungi thrive in warm, moist environment, so this type of environment can cause the fungi to naturally overpopulate. The same fungi that is responsible for causing jock itch, athlete's foot, and ringworm can cause nail infections. The people who are suffering from diabetes, have a disease that causes poor circulation, are over age 65, wear artificial nails, swim in a public swimming pool, have a nail or skin injury, or wear closed-toe shoes are at higher risk of developing the disease.

Markets Covered:

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Onychomycosis Understanding and Treatment Algorithm:

The market report provides the overview of the Onychomycosis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Onychomycosis Epidemiology:

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Onychomycosis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Onychomycosis Product Profiles & Analysis:

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Onychomycosis Market Outlook:

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Onychomycosis market.

Onychomycosis Market Share by Therapies:

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Onychomycosis Report Insights:

  • Patient Population in Onychomycosis
  • Therapeutic Approaches in Onychomycosis
  • Onychomycosis Pipeline Analysis
  • Onychomycosis Market Size and Trends
  • Onychomycosis Market Opportunities
  • Impact of upcoming Therapies in Onychomycosis

Onychomycosis Report Key Strengths:

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Onychomycosis Report Assessment:

  • Current Treatment Practices in Onychomycosis
  • Unmet Needs in Onychomycosis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Onychomycosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Onychomycosis market
  • To understand the future market competition in the Onychomycosis market.
Table of Contents
Product Code: DIMI0482

Table of Contents

1. Report Introduction

2. Onychomycosis Market Overview at a Glance

  • 2.1. Market Share Distribution of Onychomycosis in 2016
  • 2.2. Market Share Distribution of Onychomycosis in 2028

3. Disease Background and Overview: Onychomycosis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Onychomycosis in 7MM
  • 4.3. Total Prevalent Patient Population of Onychomycosis in 7MM - By Countries

5. Epidemiology of Onychomycosis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.1.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.1.4. Sex- Specific Cases of the Onychomycosis *
    • 5.1.5. Diagnosed Cases of the Onychomycosis
    • 5.1.6. Treatable Cases of the Onychomycosis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.4.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.4.4. Sex- Specific Cases of the Onychomycosis *
    • 5.4.5. Diagnosed Cases of the Onychomycosis
    • 5.4.6. Treatable Cases of the Onychomycosis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.5.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.5.4. Sex- Specific Cases of the Onychomycosis *
    • 5.5.5. Diagnosed Cases of the Onychomycosis
    • 5.5.6. Treatable Cases of the Onychomycosis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.6.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.6.4. Sex- Specific Cases of the Onychomycosis *
    • 5.6.5. Diagnosed Cases of the Onychomycosis
    • 5.6.6. Treatable Cases of the Onychomycosis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.7.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.7.4. Sex- Specific Cases of the Onychomycosis *
    • 5.7.5. Diagnosed Cases of the Onychomycosis
    • 5.7.6. Treatable Cases of the Onychomycosis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.8.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.8.4. Sex- Specific Cases of the Onychomycosis *
    • 5.8.5. Diagnosed Cases of the Onychomycosis
    • 5.8.6. Treatable Cases of the Onychomycosis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Onychomycosis
    • 5.9.3. Sub-Type Specific cases of the Onychomycosis *
    • 5.9.4. Sex- Specific Cases of the Onychomycosis *
    • 5.9.5. Diagnosed Cases of the Onychomycosis
    • 5.9.6. Treatable Cases of the Onychomycosis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Onychomycosis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Onychomycosis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Onychomycosis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Onychomycosis
  • 12.2. 7MM Percentage Share of drugs marketed for Onychomycosis
  • 12.3. 7MM Market Sales of Onychomycosis by Products

13. Onychomycosis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Onychomycosis in United States
    • 13.1.2. Percentage Share of drugs marketed for Onychomycosis in United States
    • 13.1.3. Market Sales of Onychomycosis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Onychomycosis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Onychomycosis in Germany
      • 13.2.1.3. Market Sales of Onychomycosis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Onychomycosis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Onychomycosis in France
      • 13.2.2.3. Market Sales of Onychomycosis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Onychomycosis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Onychomycosis in Italy
      • 13.2.3.3. Market Sales of Onychomycosis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Onychomycosis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Onychomycosis in Spain
      • 13.2.4.3. Market Sales of Onychomycosis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Onychomycosis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Onychomycosis in United Kingdom
      • 13.2.5.3. Market Sales of Onychomycosis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Onychomycosis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Onychomycosis in Japan
    • 13.3.3. Market Sales of Onychomycosis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Onychomycosis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Onychomycosis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Onychomycosis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Onychomycosis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Onychomycosis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Onychomycosis in United States (2016-2028)
  • Table 7: Treatable Cases of the Onychomycosis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Onychomycosis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Onychomycosis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Onychomycosis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Onychomycosis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Onychomycosis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Onychomycosis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Onychomycosis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Onychomycosis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Onychomycosis in France (2016-2028)
  • Table 17: Treatable Cases of the Onychomycosis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Onychomycosis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Onychomycosis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Onychomycosis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Onychomycosis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Onychomycosis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Onychomycosis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Onychomycosis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Onychomycosis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Onychomycosis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Onychomycosis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Onychomycosis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Onychomycosis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Onychomycosis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Onychomycosis in UK (2016-2028)
  • Table 32: Treatable Cases of the Onychomycosis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Onychomycosis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Onychomycosis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Onychomycosis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Onychomycosis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Onychomycosis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 45: United States-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 51: France-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 59: UK-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 60: UK-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 61: UK-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Onychomycosis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Onychomycosis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Onychomycosis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Onychomycosis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Onychomycosis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Onychomycosis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Onychomycosis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Onychomycosis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Onychomycosis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Onychomycosis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Onychomycosis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Onychomycosis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Onychomycosis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Onychomycosis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Onychomycosis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Onychomycosis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Onychomycosis in France (2016-2028)
  • Figure 17: Treatable Cases of the Onychomycosis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Onychomycosis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Onychomycosis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Onychomycosis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Onychomycosis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Onychomycosis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Onychomycosis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Onychomycosis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Onychomycosis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Onychomycosis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Onychomycosis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Onychomycosis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Onychomycosis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Onychomycosis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Onychomycosis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Onychomycosis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Onychomycosis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Onychomycosis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Onychomycosis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Onychomycosis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Onychomycosis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 51: France-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 59: UK-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 60: UK-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 61: UK-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Onychomycosis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Onychomycosis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Onychomycosis by Therapies in USD MM (2016-2028)
Back to Top